High Hopes For Heidelberg Pharma With Huadong Onboard
Pact With Chinese Group Close To Completion
Executive Summary
CEO Jan Schmidt-Brand tells Scrip that with another reliable long-term investor on the team alongside major shareholder Dievini, Heidelberg is well positioned to advance its amanitin-targeted antibody-drug conjugate candidates.
You may also be interested in...
Asia Deal Watch: Astellas, GO Team Up On Targeted Cancer Therapy
Astellas subsidiary Xyphos will partner with GO to discover novel antibodies against two glycoprotein targets. SciNeuro picks up abandoned GSK programs in cardiovascular medicine for potential use in the neurodegeneration space.
Asarina And Emalex Carry The Torch For Tourette's
The pipeline to treat the neurological disorder, which is characterized by uncontrolled rapid and repeated movements or sounds, is very thin but a couple of biotechs either side of the Atlantic are making progress.
Novartis Excited About Iptacopan But Downcast After Huntington’s Blow
The Swiss major is close to its first submission for ‘pipeline in a pill’ iptacopan but has conceded defeat with branaplam as a potential treatment for Huntington’s disease.